MedPacto, Inc. (KOSDAQ:235980)
South Korea · Delayed Price · Currency is KRW 2,895.00
-90.00 (-3.02%)
Oct 12, 2026, 3:30 PM KST
MedPacto Revenue
MedPacto had revenue of 1.05B KRW in the quarter ending June 30, 2026, with 24.97% growth. This brings the company's revenue in the last twelve months to 4.99B, up 293.41% year-over-year. In the year 2025, MedPacto had annual revenue of 3.90B. That makes MedPacto the 40,827th largest company in the world by revenue and 2,519th in South Korea.
Revenue (ttm)
4.99B
Revenue Growth
+293.41%
P/S Ratio
19.87
Revenue / Employee
89.19M
Employees
56
Market Cap
99.23B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.90B | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| Prestige BioPharma | 26.07B |
| GeneOne Life Science | 12.37B |
| Anterogen.Co.,Ltd. | 8.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| ENCell | 4.16B |